TABLE 7.
Reported drug resistance profiles of PMF- and ATP-dependent multidrug transportersa
| Drug | MFS
|
SMR
|
RND
|
MATE
|
ABC
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12-TMS cluster
|
14-TMS cluster
|
|||||||||||||||||||||||||||||||||||||||
| Bcr | Blt | Bmr | Cmr | EmrD | LmrP | MdfA | NorA | PmrA | Tap | Bmr3 | EmrB | LfrA | QacA | QacB | VceB | EbrAB | EmrE | Mmr | QacE | QacEΔ1 | QacG | QacH | Smr | TehA | YkkCD | AcrB | AcrF | AmrB | HI0895 | MexB | MexD | MexF | MexY | MtrD | YhiV | NorM | YdhE | HorA | LmrA | |
| Aminoglycosides | − | − | − | +b | + | − | − | − | + | − | + | − | −c | − | + | − | + | + | ||||||||||||||||||||||
| β-Lactams | ||||||||||||||||||||||||||||||||||||||||
| Carbapenems | − | − | − | + | − | − | ||||||||||||||||||||||||||||||||||
| Cephalosporins | − | − | − | − | + | + | ||||||||||||||||||||||||||||||||||
| Penicillins | − | + | + | − | − | + | −d | + | + | |||||||||||||||||||||||||||||||
| Chloramphenicol | + | − | − | − | + | + | − | − | − | + | + | − | − | − | + | + | − | − | + | + | + | − | − | + | ||||||||||||||||
| Glycopeptides | − | − | − | + | − | |||||||||||||||||||||||||||||||||||
| Lincosamides | + | − | − | + | ||||||||||||||||||||||||||||||||||||
| Macrolides | ||||||||||||||||||||||||||||||||||||||||
| 14-Membered | − | + | + | + | − | − | − | + | − | + | + | + | + | + | + | + | + | − | + | + | − | − | + | |||||||||||||||||
| 15-Membered | + | + | + | + | ||||||||||||||||||||||||||||||||||||
| 16-Membered | − | |||||||||||||||||||||||||||||||||||||||
| Novobiocin | + | − | + | + | + | + | + | + | ||||||||||||||||||||||||||||||||
| Quinolones | ||||||||||||||||||||||||||||||||||||||||
| Hydrophilic | + | +e | − | − | − | + | +e | + | − | + | − | + | − | − | − | + | − | − | + | + | + | + | − | + | + | |||||||||||||||
| Hydrophobic | +e | − | − | − | − | +e | − | − | − | + | − | + | + | − | + | + | + | − | + | |||||||||||||||||||||
| Rifampin | + | + | − | + | + | − | + | + | − | + | + | |||||||||||||||||||||||||||||
| Sulfonamides | + | − | + | |||||||||||||||||||||||||||||||||||||
| Tetracyclines | − | + | + | + | − | + | −f | + | − | − | + | − | − | + | + | + | − | + | + | + | + | − | − | + | ||||||||||||||||
| Trimethoprim | − | − | − | − | + | + | − | |||||||||||||||||||||||||||||||||
a
+, resistance; −, no resistance.
b
MdfA expression confers resistance to kanamycin and neomycin but hypersusceptibility to spectinomycin.
c
MexCD expression confers hypersusceptibility to carbenicillin but does not affect resistance to ampicillin and penicillin.
d
MexCD expression confers hypersusceptibility to gentamicin.
e
Bmr and NorA confer a higher level of resistance to hydrophilic quinolones than to hydrophobic quinolones.
f
LfrA confers resistance to tetracycline but not to minocycline and chlortetracycline.